About the Report
- The ADC space is continuing to grow with a 22% average annual growth rate in ADCs entering the clinic between 2011 – 2021, with a record high of 33 new drugs entering the clinic in 2022 so far.
- The turbulent global market conditions are presenting lots of business opportunities, with 7 collaborations and 10 license agreements among ADC developers in H1 2022.
- Following on from previous activity, H1 of 2022 has seen a focus on the clinical studies at the late development stage. We can expect more approvals from the rest of the year and next.
- Download the comprehensive Full Landscape 2022 analysis for a detailed report of all updates in the ADC field so far this year.
Find out more
Speak with our expert Team
Our dedicated team is on hand to showcase how Beacon can help you find the answers to your ADC questions.
About Beacon Targeted Therapies
We are a clinical trial and pipeline database solution, designed in partnership with pharmaceutical professionals. We track targeted therapies to provide accurate, in-depth and real-time information in the rapidly evolving landscape of drug development.
Learn more about how our clinical trials and drug database solutions can be tailored to your research requirements
